Página principal > Resultados de la búsqueda: Schjesvold, Fredrik
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
11 p, 396.3 KB Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics / Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ; Schjesvold, Fredrik (University of Oslo) ; Weisel, Katja (University Medical Center Hamburg-Eppendorf) ; Moreau, Philippe (University Hospital Hôtel-Dieu) ; Anderson, Larry D. (University of Texas Southwestern Medical Center) ; White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Sonneveld, Pieter (Erasmus MC Cancer Institute) ; Engelhardt, Monika (Universitätsklinikum Freiburg) ; Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Corso, Alessandro (Hospital of Legnano) ; Dürig, Jan (University Hospital Essen (Alemanya)) ; Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ; Salomo, Morten (Copenhagen University Hospital) ; Beksac, Meral (Ankara University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ; Liberati, Anna Marina (University of Perugia) ; Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ; Robak, Pawel (Medical University of Lodz) ; Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ; Yagci, Munci (Gazi University Medical Faculty) ; Vural, Filiz (Ege University) ; Kanate, Abraham (West Virginia University) ; Jiang, Ruiyun (Bristol Myers Squibb) ; Grote, Lara (Bristol Myers Squibb) ; Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ; Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83  
Registro completo - Creative Commons
2.
16 p, 1.0 MB Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment / Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dimopoulos, Meletios (National and Kapodistrian University) ; Schjesvold, Fredrik (University of Oslo) ; Beksac, Meral (Ankara Üniversitesi Tip Fakültes) ; Facon, Thierry (Hôpital Claude Huriez CHU de Lille) ; Dhanasiri, Sujith (Celgene International Sàrl. a Bristol-Myers Squibb Company (Suïssa)) ; Guo, Shien (Evidera) ; Mu, Yutian (Evidera) ; Hong, Kevin (Bristol Myers Squibb) ; Gentili, Christian (Bristol Myers Squibb) ; Galli, Mónica (ASST Papa Giovanni XXIII) ; Yagci, Munci (Gazi University) ; Larocca, Alessandra (University of Torino) ; Richardson, Paul (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Weisel, Katja (University Medical Center Hamburg-Eppendorf (Alemanya))
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. [...]
2023 - 10.1016/j.clml.2023.10.009
Clinical Lymphoma, Myeloma & Leukemia, 2023  
Registro completo - Creative Commons
3.
20 p, 519.4 KB Current and novel alkylators in multiple myeloma / Schjesvold, Fredrik (University of Oslo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. [...]
2021 - 10.3390/cancers13102465
Cancers, Vol. 13 Núm. 10 (may 2021) , p. 2465  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Schjesvold, F.
1 Schjesvold, F. H.
1 Schjesvold, F.H.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos